BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BioCentury | Jan 29, 2020
Product Development

Industry leaders applaud CVS zero co-pay diabetes drug access

CVS is answering the call to decrease the cost burden of diabetes medications on patients with a new plan that eliminates co-pays, and industry leaders committed to the social contract are applauding the news as...
BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

Innovator pharmaceutical manufacturers hope the new “phase one” U.S.-China trade deal will create a cease-fire in the stealth war on pharma IP in China. The deal, announced Dec. 13, comes at the end of a...
BC Extra | Nov 13, 2019
Clinical News

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BC Extra | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

FDA approves Bavarian Nordic’s smallpox/monkeypox vaccine  FDA approved Jynneos MVA-BN from Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) to prevent smallpox and monkeypox, making the vaccine the only approved non-replicating smallpox vaccine in the U.S. and the...
BC Extra | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Rakuten Medical raises another $100 million  Rakuten Medical Inc. (San Diego, Calif.) raised $100 million in a series C-1 round from existing investor Rakuten Inc. (Tokyo:4755), giving the Japanese internet giant a 22.6% stake. The...
BC Extra | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
BC Extra | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis  Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
Items per page:
1 - 10 of 719